Prothena Corporation plc (PRTA) Income Statement Analysis

See more : BRT Apartments Corp. (BRT) Income Statement Analysis – Financial Results

Complete financial analysis of Prothena Corporation plc (PRTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prothena Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Shanghai Titan Scientific Co.,Ltd. (688133.SS) Income Statement Analysis – Financial Results
Lenta International public joint-stock company (LENTY) Income Statement Analysis – Financial Results
Yuexiu Transport Infrastructure Limited (1052.HK) Income Statement Analysis – Financial Results
Granite Ridge Resources, Inc (GRNT) Income Statement Analysis – Financial Results
UTIQUE ENTERPRISES LIMITED (UTIQUE.BO) Income Statement Analysis – Financial Results

Prothena Corporation plc (PRTA)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.prothena.com

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	91.37M	53.91M	200.58M	853.00K	814.00K	955.00K	27.52M	1.06M	1.61M	50.85M	676.00K	2.66M	507.00K	1.24M
Cost of Revenue	220.57M	6.74M	82.28M	74.88M	50.84M	101.18M	134.55M	119.53M	58.44M	38.45M	26.05M	34.14M	0.00	0.00
Gross Profit	-129.20M	47.16M	118.29M	-74.03M	-50.02M	-100.23M	-107.03M	-118.48M	-56.83M	12.40M	-25.38M	-31.48M	507.00K	1.24M
Gross Profit Ratio	-141.40%	87.49%	58.98%	-8,678.90%	-6,145.21%	-10,495.08%	-388.92%	-11,230.24%	-3,536.53%	24.39%	-3,753.85%	-1,184.39%	100.00%	100.00%
Research & Development	220.57M	135.56M	82.28M	74.88M	50.84M	101.18M	134.55M	119.53M	58.44M	38.45M	26.05M	34.14M	24.17M	9.79M
General & Administrative	61.84M	49.90M	46.32M	38.70M	35.74M	42.48M	48.23M	41.06M	23.11M	19.05M	15.05M	9.93M	5.58M	3.62M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	61.84M	49.90M	46.32M	38.70M	35.74M	42.48M	48.23M	41.06M	23.11M	19.05M	15.05M	9.93M	5.58M	3.62M
Other Expenses	0.00	5.95M	-54.00K	1.31M	8.40M	2.74M	-2.35M	571.00K	26.00K	310.00K	-225.00K	0.00	0.00	0.00
Operating Expenses	282.41M	185.46M	128.60M	113.59M	86.57M	143.67M	182.77M	160.59M	81.54M	57.50M	41.10M	44.07M	29.75M	13.41M
Cost & Expenses	282.41M	185.46M	128.60M	113.59M	86.57M	143.67M	182.77M	160.59M	81.54M	57.50M	41.10M	44.07M	29.75M	13.41M
Interest Income	31.01M	6.35M	42.00K	1.37M	8.20M	6.39M	3.55M	0.00	196.00K	79.00K	71.00K	5.00K	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	8.20M	3.70M	3.69M	0.00	0.00	0.00	154.00K	0.00	0.00	0.00
Depreciation & Amortization	928.00K	6.74M	6.80M	6.98M	6.82M	3.22M	3.07M	2.43M	806.00K	743.00K	660.00K	468.00K	391.00K	191.00K
EBITDA	-190.11M	-131.56M	71.98M	-111.22M	-78.94M	-152.90M	-152.19M	-156.54M	-79.13M	-5.91M	-39.77M	-40.94M	-28.85M	-11.97M
EBITDA Ratio	-208.06%	-244.05%	35.88%	-13,216.18%	-10,542.87%	-13,252.88%	-564.17%	-15,121.80%	-4,974.30%	-13.07%	-5,980.33%	-1,557.94%	-5,690.93%	-963.07%
Operating Income	-191.04M	-131.56M	71.98M	-112.73M	-85.70M	-158.86M	-155.25M	-159.54M	-79.94M	-6.65M	-40.43M	-41.41M	-29.24M	-12.16M
Operating Income Ratio	-209.08%	-244.05%	35.88%	-13,216.18%	-10,527.89%	-16,634.03%	-564.17%	-15,121.80%	-4,974.30%	-13.07%	-5,980.33%	-1,557.94%	-5,768.05%	-978.44%
Total Other Income/Expenses	30.56M	5.95M	-54.00K	1.31M	8.40M	2.74M	-2.35M	571.00K	26.00K	310.00K	-154.00K	5.00K	0.00	0.00
Income Before Tax	-160.48M	-125.61M	71.92M	-111.43M	-77.30M	-156.12M	-157.60M	-158.96M	-79.91M	-6.34M	-40.58M	-41.41M	-29.24M	-12.16M
Income Before Tax Ratio	-175.64%	-233.01%	35.86%	-13,062.95%	-9,496.07%	-16,347.12%	-572.71%	-15,067.68%	-4,972.68%	-12.47%	-6,003.11%	-1,557.75%	-5,768.05%	-978.44%
Income Tax Expense	-13.45M	-8.66M	4.95M	-283.00K	379.00K	-470.00K	-4.37M	1.14M	701.00K	811.00K	415.00K	6.00K	426.00K	320.00K
Net Income	-147.03M	-116.95M	66.98M	-111.14M	-77.68M	-155.65M	-153.24M	-160.11M	-80.61M	-7.15M	-41.00M	-41.41M	-29.67M	-12.48M
Net Income Ratio	-160.91%	-216.95%	33.39%	-13,029.78%	-9,542.63%	-16,297.91%	-556.84%	-15,176.11%	-5,016.30%	-14.06%	-6,064.50%	-1,557.98%	-5,852.07%	-1,004.18%
EPS	-2.76	-2.47	1.51	-2.78	-1.95	-3.93	-4.07	-4.66	-2.66	-0.29	-2.20	-2.84	-1.68	-0.71
EPS Diluted	-2.76	-2.47	1.38	-2.78	-1.95	-3.93	-4.07	-4.66	-2.66	-0.29	-2.20	-2.84	-1.68	-0.71
Weighted Avg Shares Out	53.22M	47.37M	44.23M	39.92M	39.88M	39.56M	37.65M	34.35M	30.33M	24.67M	18.62M	14.59M	17.68M	17.68M
Weighted Avg Shares Out (Dil)	53.22M	47.37M	48.46M	39.92M	39.88M	39.56M	37.65M	34.35M	30.33M	24.67M	18.62M	14.59M	17.68M	17.68M

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

July 11, 2023businesswire.com

DUBLIN--(BUSINESS WIRE)---- $PRTA #AAIC2023--Prothena today announced participation in the Alzheimer's Association International Conference® 2023 (AAIC®) being held July 16-20, 2023.

Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY

July 11, 2023zacks.com

Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

July 10, 2023businesswire.com

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Bristol Myers Squibb exercised its option to obtain exclusive worldwide commercial rights for PRX005.

Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future

May 7, 2023seekingalpha.com

Prothena's recent collaboration with Walgreens is expected to drive recruitment for Prothena's ongoing ASCENT-2 safety and tolerability trial of PRX012. PRX012, an anti-amyloid beta antibody, has shown superior binding and clearance of toxic Aβ species compared to other approved and...

Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates

May 5, 2023zacks.com

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates

May 4, 2023zacks.com

Prothena (PRTA) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.78 per share a year ago.

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer's Disease Clinical Trial

April 13, 2023businesswire.com

DEERFIELD, Ill. & DUBLIN--(BUSINESS WIRE)--Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena's ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under...

Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?

April 6, 2023zacks.com

Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.

Prothena Corporation plc (PRTA) Q4 2022 Earnings Call Transcript

February 24, 2023seekingalpha.com

Prothena Corporation plc (NASDAQ:PRTA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Eric Endicott - Senior Vice President, Corporate Affairs and Communications Gene Kinney - President and Chief Executive Officer Hideki Garren - Chief...